Oncology Corporate Profile
ICT has developed a unique and highly promising strategy for preparing vaccines for cancer therapy that have special advantages other types of cancer vaccines. The treatment consists of immunization with a vaccine that is designed to induce a powerful immune response against microscopic nests cancer cells remaining in patients who have completed conventional treatment (usually surgery, chemo/hormonal therapy and X-ray). Microscopic nests of residual cancer cells are the most common source of recurrence of the disease. The Company's initial focus is for patients with lung or breast cancer.
11/3/2016 06:56 am
(Boston Globe/Associated Press) Nov 3, 2016 - Doctors have found a disturbing downside to some powerful new drugs that harness the immune system to fight cancer: In rare cases, they may cause potentially fatal heart damage, especially when used together.
10/27/2016 11:52 am
(Yahoo! Finance) Oct 27, 2016 - Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that it has entered into a clinical trial collaboration agreement with Merck & Co., Inc., for the assessment of Adaptimmune’s NY-ESO SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapy in combination with MSD’s anti-programmed death-1 (PD-1) inhibitor, KEYTRUDA® (pembrolizumab), in patients with multiple myeloma.
10/27/2016 11:43 am
(MIT News) Oct 26, 2016 - After a young man with acute leukemia was treated successfully with traditional chemotherapy, he found himself facing a tough decision.
10/24/2016 12:03 pm
(Reuters Health) Oct 21, 2016 - People with type 1 diabetes often develop other autoimmune disorders, such as thyroid and gastrointestinal diseases, and a recent study yields new information about this link.
10/19/2016 11:42 am
(Genetic Engineering & Biotechnology News) Oct 17, 2016 - Accurexa will partner with StemImmune to develop its stem cell-mediated cancer immunotherapy, the companies said today, through a collaboration whose value was not disclosed.
10/18/2016 11:53 am
(FoxNews.com/Associated Press) Oct 18, 2016 - Drugmaker Pfizer said Monday that it will launch a less-expensive version of rival Johnson & Johnson's blockbuster immune disorder drug, Remicade.
10/18/2016 11:33 am
(Yahoo! Finance) Oct 18, 2016 - Adaptimmune Therapeutics plc today announced that it has initiated a Phase I triple tumor study using its wholly owned MAGE-A10 SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapy in patients with inoperable or metastatic urothelial cancer (transitional cell cancer of the bladder, ureter, or renal pelvis), melanoma, or squamous cell carcinoma of the head and neck.
10/17/2016 11:18 am
(The Wistar Institute) Oct 14, 2016 - While the role of estrogen signaling in tumor development is well understood in breast and ovarian cancer, its role in anti-tumor immunity has not been extensively studied. However, new research from The Wistar Institute showed that estrogen signaling was responsible for immunosuppressive effects in the tumor microenvironment across cancer types.
10/12/2016 11:06 am
(Yahoo! Finance) Oct 12, 2016 - Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that its amended protocol using its NY-ESO SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapy in ovarian cancer patients with treatment resistant or refractory metastatic ovarian cancer is now actively recruiting.
10/11/2016 01:06 pm
(Yahoo! Finance) Oct 11, 2016 - CA-327, a PD-L1/TIM3 dual antagonist designed and optimized by Aurigene, licensed as the 2nd oral small molecule immuno-oncology development candidate under the Curis Aurigene collaboration.
10/5/2016 11:11 am
(Cancer Research UK/Press Association) Oct 5, 2016 - Certain microbes in the gut can help improve the effectiveness of chemotherapy drugs, according to a new study.
9/29/2016 12:29 pm
(Boehringer Ingelheim) Sept 29, 2016 - Boehringer Ingelheim and Sarah Cannon Research Institute, the research arm of Sarah Cannon, the global cancer institute of HCA, announced today a new strategic collaboration. This partnership brings together Boehringer Ingelheim's extensive experience in cancer drug development and Sarah Cannon's expertise and leadership in designing and optimizing clinical trials. The partnership will help bring innovative cancer treatments to patients with unmet medical needs.
9/28/2016 11:59 am
(Stanford Medicine/Scope blog) Sept 27, 2016 - Recently, a team of Stanford researchers was testing a new way to fight cancer when something strange happened.
9/27/2016 10:48 am
(NASDAQ) Sept 26, 2016 - Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, and The University of Texas MD Anderson Cancer Center announced today that they have entered into a multi-year strategic alliance designed to expedite the development of novel adoptive T-cell therapies for multiple types of cancer.
9/26/2016 11:32 am
(Reuters) Sept 26, 2016 - Johnson & Johnson said on Monday that the U.S. Food and Drug Administration approved the company's blockbuster psoriasis drug, Stelara, for use in adults with Crohn's disease.
9/26/2016 11:08 am
(AACR) Sept 26, 2016 - Among patients with stage IV melanoma who were being treated with the immunotherapeutic pembrolizumab (Keytruda), the ratio of a particular subset of immune cells in the blood to tumor burden correlated with clinical response, according to data presented at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held Sept. 25–28.